Featured Research

from universities, journals, and other organizations

Molecular rationale for combining targeted agents to treat breast cancer

Date:
January 16, 2011
Source:
Ohio State University Medical Center
Summary:
A new study provides a rational for treating breast cancer by combining two kinds of targeted agents, one that inhibits an overactive, cancer-causing signaling pathway in cancer cells and one that reverses changes that silence genes that normally prevent cancer. Both types of agents are currently available and being evaluated individually in clinical trials.

A new study by Ohio State University cancer researchers provides a rational for treating breast cancer by combining two kinds of targeted agents, one that inhibits an overactive, cancer-causing pathway in cancer cells and one that reverses changes that silence genes that normally prevent cancer. Both types of agents are currently available and being evaluated individually in clinical trials, the researchers note.

The findings, published online in the journal Cancer Research, show that abnormal activation of the PI3K/AKT signaling pathway leads to the silencing of a number of tumor-suppressor genes that regulate cell proliferation, survival and motility and angiogenesis.

The laboratory and animal study also shows that combining an agent that inhibits PI3K and a drug that reverse the epigenetic changes that cause gene silencing significantly slows tumor growth.

"The link we have uncovered between PI3K/AKT signaling and epigenetic silencing offers a new therapeutic strategy for breast cancer that combines a PI3K/AKT inhibitor and agents that target epigenetic changes," says study leader Tim H-M Huang, professor of molecular virology, immunology and medical genetics at the Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

"Our studies show that, in models, these agents work together synergistically to reverse gene silencing and suppress cancer-cell growth, suggesting that combining these targeted agents might improve breast-cancer therapy."

Cancer development typically involves the abnormal activation of genes that regulate cell growth and the silencing of genes that normally prevent cancer development. The activation of one or more "oncogenes" and the silencing of tumor-suppressor genes are usually considered separate events that together lead to cancer. This and earlier studies led by Huang show that the two events are sometimes linked.

Huang and his colleagues are now planning a clinical trial for patients with metastatic breast cancer that will investigate the use of combined targeted drugs.

Funding from the National Cancer Institute, the Department of Defense and the Susan G. Komen Breast Cancer Foundation supported this research.

Other researchers involved in this study were Tao Zuo, Ta-Ming Liu, Xun Lan, Yu-I Weng, Rulong Shen, Fei Gu, Yi-Wen Huang, Sandya Liyanarachchi, Daniel E. Deatherage, Pei-Yin Hsu, Cenny Taslim, Bhuvaneswari Ramaswamy, Charles L. Shapiro, Huey-Jen L. Lin and Victor X. Jin of Ohio State University; and Alfred S. L. Cheng of The Chinese University of Hong Kong.


Story Source:

The above story is based on materials provided by Ohio State University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Ohio State University Medical Center. "Molecular rationale for combining targeted agents to treat breast cancer." ScienceDaily. ScienceDaily, 16 January 2011. <www.sciencedaily.com/releases/2011/01/110114100957.htm>.
Ohio State University Medical Center. (2011, January 16). Molecular rationale for combining targeted agents to treat breast cancer. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2011/01/110114100957.htm
Ohio State University Medical Center. "Molecular rationale for combining targeted agents to treat breast cancer." ScienceDaily. www.sciencedaily.com/releases/2011/01/110114100957.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins